Life, Journal Year: 2023, Volume and Issue: 13(12), P. 2322 - 2322
Published: Dec. 11, 2023
COVID-19 convalescent plasma (CCP) has represented the frontline response to pandemic, largely because of encouraging historical evidences in previous pandemics, biological plausibility, and initial unavailability targeted antivirals. Unfortunately, investigator-initiated randomized clinical trials 2020, launched during a stressful pandemic peak, were designed mostly at addressing main unmet need, i.e., treating critically ill hospitalized patients who unlikely benefit from any antiviral therapy. The failure most these drugs, combination with lack sponsor, led false belief that was useless. With relaxing stages, have instead mounted that, when administered properly (i.e., within 5 days onset symptoms high titers neutralizing antibodies), CCP is as effective other antivirals preventing disease progression outpatients, also reduces mortality patients. Recently, focus use been on immunosuppressed persistent seronegativity infection, where trial shown reduction mortality. Lessons learnt will be utmost importance for future pandemics.
Language: Английский